Search - tctmd.com

Displaying 21 - 40 of 243

Sort: Relevancy | Date

Presentation TCT 2023

Does Polymer Coating Matter? Biodegradable vs Durable vs Polymer-Free

Presenter: Stephan Windecker

October 26, 2023

Presentation TCT 2023

TCT 418: Impact of diabetes on clinical outcomes after percutaneous coronary intervention: 5-year results of the SORTOUT IX trial comparing the polymer-free biolimus A9-coated stent to the ultra-thin strut biodegradable polymer sirolimus-eluting stent

Presenter: Kirstine Hansen

October 25, 2023

Presentation TCT 2023

TCT 522: Ultrathin Strut Biodegradable Polymer-coated Sirolimus-eluting Stents in an All-comers Patient Population – The Prospective S-FLEX UK-II Registry

Presenter: Azfar Zaman

October 25, 2023

Presentation TCT 2023

TCT 708: Five-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stents With Biodegradable Polymer. From the SORT OUT VII Trial

Presenter: Jens Trøan

October 25, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2023

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Presenter: Giovanni Esposito

October 25, 2023

TCT 669: Impact of ACS on Long-Term Clinical Outcomes After PCI With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Presentation TCT 2023

TCT 669: Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Presenter: Manijeh Noori

October 24, 2023

News Conference News ESC 2023

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Michael O'Riordan

August 26, 2023

Presentation TCT 2022

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

Presenter: Jonas Haener

September 19, 2022

Presentation TCT 2022

TCT 62: Novel, Biodegradable PLA/PLGA Amorphous Polymer Scaffold In The Porcine Coronary Restenosis Model.

Presenter: Piotr Buszman

September 17, 2022

Presentation TCT 2022

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Presenter: Gustavo Araújo

September 17, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

Presentation TCT 2020

The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents after percutaneous coronary intervention in patients with Acute Coronary Syndrome

Presenter: Hyo-Soo Kim

October 17, 2020

Advertisement

Does Polymer Coating Matter? Biodegradable vs Durable vs Polymer-Free

TCT 418: Impact of diabetes on clinical outcomes after percutaneous coronary intervention: 5-year results of the SORTOUT IX trial comparing the polymer-free biolimus A9-coated stent to the ultra-thin strut biodegradable polymer sirolimus-eluting stent

TCT 522: Ultrathin Strut Biodegradable Polymer-coated Sirolimus-eluting Stents in an All-comers Patient Population – The Prospective S-FLEX UK-II Registry

TCT 708: Five-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stents With Biodegradable Polymer. From the SORT OUT VII Trial

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

TCT 669: Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

TCT 62: Novel, Biodegradable PLA/PLGA Amorphous Polymer Scaffold In The Porcine Coronary Restenosis Model.

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents after percutaneous coronary intervention in patients with Acute Coronary Syndrome

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content